Wegovy cost in 2026: list price, self-pay, and the $25 copay

Like every GLP-1, Wegovy has more than one price, and the gap between them is enormous. The thousand-dollar figure in the headlines is a list price; what an actual person pays depends on their insurance, Novo Nordisk’s direct self-pay program, and whether a savings offer applies. Here is the current breakdown, verified from Novo’s own pages as of June 2026. For the mechanics of why GLP-1 prices vary so wildly, see our explainer on GLP-1 cost and insurance coverage.

List price vs what you actually pay

Wegovy’s monthly list price is approximately $1,349 across all five pen doses.^[1] As with every drug in this class, that sticker is largely theoretical: people pay through insurance or through Novo’s self-pay program, and both land far below list. The right question isn’t “what does Wegovy cost?” but “what does it cost through my route?”

The self-pay tiers (no insurance)

For people paying cash, Novo’s NovoCare program prices the injectable pen at $199/month for the first two months (the 0.25 mg and 0.5 mg starting doses, an intro offer running through June 30, 2026), then $349/month for standard doses.^[2] The higher-strength Wegovy HD 7.2 mg pen is $399/month, and the newer oral pill starts at $149/month (for the 1.5 mg and 4 mg doses; the 4 mg offer runs through August 31, 2026, then rises to $199).^[2] Note that the widely-repeated “$499 a month” figure is now out of date — Novo restructured its self-pay pricing downward, and these lower tiers supersede it.

The savings offer (if you’re commercially insured)

If you have commercial insurance that covers Wegovy, Novo’s savings offer can bring your copay to as little as $25 per 28-day fill, with a maximum savings of $100 per month.^[2] As with every manufacturer card, the deepest help goes to people whose plans already cover the drug; the offer reduces a copay, it doesn’t conjure coverage where there is none.

Compounded semaglutide is no longer a legal discount

Through the shortage, compounded semaglutide was a common cash workaround. That pathway has largely closed. The FDA declared the semaglutide shortage resolved in early 2025, ending the broad compounding exceptions, and in May 2026 the FDA proposed to exclude semaglutide (along with tirzepatide and liraglutide) from the list of bulk substances outsourcing facilities may compound.^[3] A “compounded semaglutide” offer in 2026 is operating in a shrinking, legally contested space — not a settled, cheaper version of Wegovy.

Why cost is a clinical variable

Affordability isn’t separate from whether Wegovy works, because semaglutide only keeps working while you keep taking it. Real-world studies of why people discontinue GLP-1 therapy find cost and loss of coverage among the leading reasons, alongside side effects.^[4] Because stopping reverses much of the weight loss, a price you can’t sustain is a clinical problem, not just a financial one — the plan you can keep paying for usually beats a marginally cheaper one you can’t.

The honest bottom line

With commercial insurance that covers Wegovy, the savings offer likely puts you near $25 a month. Paying cash, you’re looking at $199/month for the first two months on the pen and $349 after, or from $149 for the oral pill. On Medicare or Medicaid, the savings offer doesn’t apply and coverage is plan-dependent. Compounded semaglutide is no longer a reliable or clearly legal discount. These prices move frequently — and several carry hard expiration dates — so confirm the current figure on Novo’s site before budgeting. To weigh it against the higher-potency alternative, see Zepbound cost and Ozempic vs Wegovy; for the routes to a prescription, our guide to GLP-1 providers.